{
 "disease": "marginal-zone-lymphoma",
 "label": "Marginal zone lymphoma",
 "url": "https://usebiotransfer.org/disease/marginal-zone-lymphoma/",
 "built": "2026-09-17",
 "facts_hash": {
  "answers": "2debfea19a5d",
  "targets": "23bdf6b559a5"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-17",
  "trials": "2026-09-17"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "MYD88",
   "ensembl": "ENSG00000172936",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "KLF2",
   "ensembl": "ENSG00000127528",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    }
   ]
  },
  {
   "symbol": "NOTCH2",
   "ensembl": "ENSG00000134250",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "TAREXTUMAB": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "TNFAIP3",
   "ensembl": "ENSG00000118503",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "BIRC3",
   "ensembl": "ENSG00000023445",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "BIRINAPANT": "PHASE_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "MALT1",
   "ensembl": "ENSG00000172175",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "MEPAZINE": "UNKNOWN"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "CARD11",
   "ensembl": "ENSG00000198286",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "KMT2D",
   "ensembl": "ENSG00000167548",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "PTPRD",
   "ensembl": "ENSG00000153707",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "BTK",
   "ensembl": "ENSG00000010671",
   "n_drug_entries": 24,
   "n_distinct_drugs": 20,
   "drugs": {
    "ABIVERTINIB": "PHASE_3",
    "ACALABRUTINIB": "APPROVAL",
    "BMS-986142": "PHASE_2",
    "BRANEBRUTINIB": "PHASE_2",
    "EDRALBRUTINIB": "PHASE_2",
    "ELSUBRUTINIB": "PHASE_2",
    "EVOBRUTINIB": "PHASE_3",
    "FENEBRUTINIB": "PHASE_3",
    "IBRUTINIB": "APPROVAL",
    "MSC-2364447": "PHASE_1",
    "ORELABRUTINIB": "APPROVAL",
    "PIRTOBRUTINIB": "APPROVAL",
    "POSELTINIB": "PHASE_2",
    "RILZABRUTINIB": "APPROVAL",
    "RITLECITINIB": "APPROVAL",
    "SPEBRUTINIB": "PHASE_2",
    "TIRABRUTINIB": "APPROVAL",
    "TOLEBRUTINIB": "PREAPPROVAL",
    "VECABRUTINIB": "PHASE_1_2",
    "ZANUBRUTINIB": "APPROVAL"
   },
   "approved": [
    "ACALABRUTINIB",
    "IBRUTINIB",
    "ORELABRUTINIB",
    "PIRTOBRUTINIB",
    "RILZABRUTINIB",
    "RITLECITINIB",
    "TIRABRUTINIB",
    "ZANUBRUTINIB"
   ],
   "n_approved": 8,
   "approved_for": {
    "ACALABRUTINIB": [
     "B-cell chronic lymphocytic leukemia",
     "childhood leukemia",
     "mantle cell lymphoma"
    ],
    "IBRUTINIB": [
     "macroglobulinemia",
     "mantle cell lymphoma",
     "B-cell chronic lymphocytic leukemia"
    ],
    "ORELABRUTINIB": [],
    "PIRTOBRUTINIB": [
     "mantle cell lymphoma",
     "non-Hodgkin lymphoma"
    ],
    "RILZABRUTINIB": [
     "autoimmune thrombocytopenic purpura"
    ],
    "RITLECITINIB": [
     "alopecia areata"
    ],
    "TIRABRUTINIB": [],
    "ZANUBRUTINIB": [
     "mantle cell lymphoma",
     "B-cell chronic lymphocytic leukemia",
     "lymphoplasmacytic lymphoma",
     "Waldenstrom macroglobulinemia"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Phase 1 Clinical"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "MS4A1",
   "ensembl": "ENSG00000156738",
   "n_drug_entries": 18,
   "n_distinct_drugs": 18,
   "drugs": {
    "EPCORITAMAB": "APPROVAL",
    "FBT-A05": "PHASE_1_2",
    "GLOFITAMAB": "APPROVAL",
    "LFB-R603": "PHASE_1",
    "MOSUNETUZUMAB": "APPROVAL",
    "MT-3724": "PHASE_2",
    "OBINUTUZUMAB": "APPROVAL",
    "OCARATUZUMAB": "PHASE_2",
    "OCRELIZUMAB": "APPROVAL",
    "ODRONEXTAMAB": "APPROVAL",
    "OFATUMUMAB": "APPROVAL",
    "RITUXIMAB": "APPROVAL",
    "TOSITUMOMAB": "APPROVAL",
    "TOSITUMOMAB 131I": "PHASE_3",
    "TRU-015": "PHASE_2",
    "UBLITUXIMAB": "APPROVAL",
    "VELTUZUMAB": "PHASE_2",
    "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": "APPROVAL"
   },
   "approved": [
    "EPCORITAMAB",
    "GLOFITAMAB",
    "MOSUNETUZUMAB",
    "OBINUTUZUMAB",
    "OCRELIZUMAB",
    "ODRONEXTAMAB",
    "OFATUMUMAB",
    "RITUXIMAB",
    "TOSITUMOMAB",
    "UBLITUXIMAB",
    "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN"
   ],
   "n_approved": 11,
   "approved_for": {
    "EPCORITAMAB": [
     "follicular lymphoma",
     "B-cell non-Hodgkin lymphoma",
     "diffuse large B-cell lymphoma"
    ],
    "GLOFITAMAB": [
     "diffuse large B-cell lymphoma"
    ],
    "MOSUNETUZUMAB": [
     "follicular lymphoma"
    ],
    "OBINUTUZUMAB": [
     "follicular lymphoma",
     "B-cell chronic lymphocytic leukemia"
    ],
    "OCRELIZUMAB": [
     "multiple sclerosis",
     "diffuse large B-cell lymphoma",
     "relapsing-remitting multiple sclerosis",
     "chronic progressive multiple sclerosis"
    ],
    "ODRONEXTAMAB": [
     "follicular lymphoma"
    ],
    "OFATUMUMAB": [
     "relapsing-remitting multiple sclerosis",
     "B-cell chronic lymphocytic leukemia",
     "multiple sclerosis",
     "secondary progressive multiple sclerosis"
    ],
    "RITUXIMAB": [
     "non-Hodgkin lymphoma",
     "granulomatosis with polyangiitis",
     "B-cell chronic lymphocytic leukemia",
     "acute lymphoblastic leukemia",
     "rheumatoid arthritis",
     "microscopic polyangiitis",
     "pemphigus",
     "vasculitis"
    ],
    "TOSITUMOMAB": [
     "non-Hodgkin lymphoma"
    ],
    "UBLITUXIMAB": [
     "multiple sclerosis",
     "relapsing-remitting multiple sclerosis",
     "chronic progressive multiple sclerosis"
    ],
    "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": [
     "follicular lymphoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "OC",
     "bucket": "Approved Drug"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "BTK": {
    "n": 65,
    "n_observational": 6,
    "n_active": 35,
    "n_withdrawn": 4,
    "trials": [
     {
      "nct": "NCT04830137",
      "title": "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04840602",
      "title": "Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04883437",
      "title": "Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05006716",
      "title": "A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05131022",
      "title": "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05294731",
      "title": "Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader",
      "status": "RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05602363",
      "title": "AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-12-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05780034",
      "title": "A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05990465",
      "title": "LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06350318",
      "title": "Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06390956",
      "title": "Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)",
      "status": "RECRUITING",
      "last_update": "2025-12-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06563505",
      "title": "A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06563596",
      "title": "Epco, Zanu, Ritux for R/R FL or MZL",
      "status": "RECRUITING",
      "last_update": "2026-02-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06708897",
      "title": "A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06859008",
      "title": "Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07231952",
      "title": "A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenstr\u00f6m's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)",
      "status": "RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00849654",
      "title": "Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01479842",
      "title": "Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01955499",
      "title": "Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01974440",
      "title": "A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01980628",
      "title": "Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-10-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02109224",
      "title": "Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection",
      "status": "TERMINATED",
      "last_update": "2015-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02180711",
      "title": "Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02332980",
      "title": "Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas",
      "status": "COMPLETED",
      "last_update": "2026-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02362035",
      "title": "ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02381080",
      "title": "Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy",
      "status": "COMPLETED",
      "last_update": "2017-06-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02532257",
      "title": "Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02914938",
      "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2023-05-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02927964",
      "title": "TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-10-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02950220",
      "title": "Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03037645",
      "title": "Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers",
      "status": "TERMINATED",
      "last_update": "2020-10-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03088878",
      "title": "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-02-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03093831",
      "title": "Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma",
      "status": "TERMINATED",
      "last_update": "2023-10-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03144674",
      "title": "A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)",
      "status": "COMPLETED",
      "last_update": "2025-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03162536",
      "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03198026",
      "title": "Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03424122",
      "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",
      "status": "COMPLETED",
      "last_update": "2025-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03479268",
      "title": "Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03520920",
      "title": "BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)",
      "status": "COMPLETED",
      "last_update": "2024-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03697512",
      "title": "MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03846427",
      "title": "Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04043845",
      "title": "ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2020-02-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04116437",
      "title": "Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment",
      "status": "COMPLETED",
      "last_update": "2026-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04172246",
      "title": "Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-11-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04189952",
      "title": "Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-05-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04212013",
      "title": "A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04282018",
      "title": "Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab",
      "status": "COMPLETED",
      "last_update": "2026-02-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04646395",
      "title": "Study of Acalabrutinib and Tafasitamab in MZL Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04665115",
      "title": "Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)",
      "status": "WITHDRAWN",
      "last_update": "2022-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04836832",
      "title": "Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2022-06-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04849416",
      "title": "A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)",
      "status": "COMPLETED",
      "last_update": "2026-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04850495",
      "title": "Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05024045",
      "title": "Study of Oral LOXO-338 in Patients With Advanced Blood Cancers",
      "status": "COMPLETED",
      "last_update": "2026-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05100862",
      "title": "A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05176691",
      "title": "HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL",
      "status": "WITHDRAWN",
      "last_update": "2023-02-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05665530",
      "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05734495",
      "title": "Pirtobrutinib and Venetoclax in Waldenstr\u00f6m Macroglobulinemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05735834",
      "title": "Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05753501",
      "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06647732",
      "title": "Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07299331",
      "title": "Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07583810",
      "title": "Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07592481",
      "title": "Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-22",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07638722",
      "title": "Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT05990465",
       "title": "LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-08-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "BTK",
     "ibrutinib",
     "zanubrutinib",
     "Brukinsa",
     "acalabrutinib",
     "pirtobrutinib"
    ]
   },
   "CD20": {
    "n": 236,
    "n_observational": 13,
    "n_active": 71,
    "n_withdrawn": 12,
    "trials": [
     {
      "nct": "NCT04110301",
      "title": "MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)",
      "status": "RECRUITING",
      "last_update": "2024-11-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04186520",
      "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04669171",
      "title": "A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04830137",
      "title": "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04834024",
      "title": "MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-11-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04840602",
      "title": "Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04883437",
      "title": "Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05131022",
      "title": "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05846750",
      "title": "Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2023-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06006117",
      "title": "Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06082102",
      "title": "Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-09-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06134284",
      "title": "Clinical Study of OR for Second-line Treatment of Refractory MZL",
      "status": "RECRUITING",
      "last_update": "2024-06-11",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06149286",
      "title": "A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06190301",
      "title": "RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06350318",
      "title": "Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06390956",
      "title": "Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)",
      "status": "RECRUITING",
      "last_update": "2025-12-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06442475",
      "title": "Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06454968",
      "title": "Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.",
      "status": "RECRUITING",
      "last_update": "2024-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06478472",
      "title": "Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy",
      "status": "RECRUITING",
      "last_update": "2024-07-29",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06504940",
      "title": "Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)",
      "status": "RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06510309",
      "title": "Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06513234",
      "title": "Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas",
      "status": "RECRUITING",
      "last_update": "2024-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06563596",
      "title": "Epco, Zanu, Ritux for R/R FL or MZL",
      "status": "RECRUITING",
      "last_update": "2026-02-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06566807",
      "title": "Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06592170",
      "title": "Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)",
      "status": "RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06700798",
      "title": "Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL\uff1a A Randomized, Open Phase II Trial",
      "status": "RECRUITING",
      "last_update": "2025-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06792825",
      "title": "HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06793189",
      "title": "MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL",
      "status": "RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06905509",
      "title": "Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07022223",
      "title": "Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07208981",
      "title": "Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL",
      "status": "RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07225439",
      "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07231952",
      "title": "A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenstr\u00f6m's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)",
      "status": "RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07355699",
      "title": "Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07448324",
      "title": "Orelabrutinib Combined With Rituximab \u00b1 Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL",
      "status": "RECRUITING",
      "last_update": "2026-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07691606",
      "title": "A Study of ARC-02 in B-cell NHL",
      "status": "RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002663",
      "title": "Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies",
      "status": "COMPLETED",
      "last_update": "2023-02-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003356",
      "title": "Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-10-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003605",
      "title": "Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2015-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003663",
      "title": "Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2015-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003874",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003963",
      "title": "Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2020-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004112",
      "title": "Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-09-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004260",
      "title": "Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2011-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005592",
      "title": "Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-10-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005601",
      "title": "Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00007852",
      "title": "Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00007865",
      "title": "Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-12-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00012207",
      "title": "Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2010-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00012298",
      "title": "Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-08-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00017381",
      "title": "Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-01-09",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00026182",
      "title": "Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00026351",
      "title": "Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00031642",
      "title": "Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2023-12-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00033423",
      "title": "Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2013-12-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00040950",
      "title": "Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00052936",
      "title": "Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-05-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054639",
      "title": "Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00058227",
      "title": "Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00058292",
      "title": "Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2012-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00062296",
      "title": "Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00068315",
      "title": "Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00072514",
      "title": "Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2017-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00073918",
      "title": "Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00075946",
      "title": "Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-02-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00080886",
      "title": "Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00080925",
      "title": "T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2012-03-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00087425",
      "title": "Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2015-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00088881",
      "title": "Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2017-05-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00093769",
      "title": "Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2012-10-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110071",
      "title": "Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110149",
      "title": "Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2017-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00117156",
      "title": "Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00119392",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00142116",
      "title": "Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia",
      "status": "COMPLETED",
      "last_update": "2014-06-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00176475",
      "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease",
      "status": "TERMINATED",
      "last_update": "2013-09-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00210353",
      "title": "Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-06-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244855",
      "title": "Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244946",
      "title": "Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-03-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244985",
      "title": "Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00265928",
      "title": "Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2008-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00274794",
      "title": "VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL",
      "status": "COMPLETED",
      "last_update": "2011-03-29",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00278161",
      "title": "Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-11-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00278408",
      "title": "Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-08-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00278421",
      "title": "Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-03-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00288067",
      "title": "Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2014-10-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00295932",
      "title": "Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-11-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00387959",
      "title": "Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00392691",
      "title": "Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment",
      "status": "COMPLETED",
      "last_update": "2019-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00397800",
      "title": "Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2012-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00398372",
      "title": "Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment",
      "status": "COMPLETED",
      "last_update": "2011-06-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00416923",
      "title": "Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-02-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00425802",
      "title": "Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00438880",
      "title": "Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00453102",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-01-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00493454",
      "title": "Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas",
      "status": "TERMINATED",
      "last_update": "2013-05-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00496873",
      "title": "Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan",
      "status": "COMPLETED",
      "last_update": "2023-03-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00521261",
      "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2014-03-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00536978",
      "title": "Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2020-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00546377",
      "title": "Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2016-05-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00551239",
      "title": "Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2020-10-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00556699",
      "title": "A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00561756",
      "title": "Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-11-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00577278",
      "title": "A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan",
      "status": "COMPLETED",
      "last_update": "2024-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00596804",
      "title": "Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00601718",
      "title": "Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-05-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00617929",
      "title": "Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00621452",
      "title": "Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00625729",
      "title": "Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00656812",
      "title": "Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-12-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00691015",
      "title": "Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2017-06-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00691652",
      "title": "Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2019-11-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00695786",
      "title": "Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00711828",
      "title": "Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00720135",
      "title": "Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00720876",
      "title": "Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00726700",
      "title": "Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00772668",
      "title": "Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL",
      "status": "TERMINATED",
      "last_update": "2017-12-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00783367",
      "title": "Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas",
      "status": "COMPLETED",
      "last_update": "2023-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00784927",
      "title": "Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-10-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00801281",
      "title": "First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.",
      "status": "COMPLETED",
      "last_update": "2017-07-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00818961",
      "title": "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2013-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00867529",
      "title": "Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-01-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00877214",
      "title": "Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas",
      "status": "UNKNOWN",
      "last_update": "2024-08-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00880815",
      "title": "Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2019-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00927797",
      "title": "Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)",
      "status": "UNKNOWN",
      "last_update": "2009-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00980395",
      "title": "Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00989586",
      "title": "Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-02-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00991211",
      "title": "Bendamustine Plus Rituximab Versus CHOP Plus Rituximab",
      "status": "COMPLETED",
      "last_update": "2024-08-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01015248",
      "title": "Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-09-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01044745",
      "title": "Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2023-09-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01045928",
      "title": "Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2015-11-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01116232",
      "title": "Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation",
      "status": "TERMINATED",
      "last_update": "2019-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01119794",
      "title": "Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab",
      "status": "TERMINATED",
      "last_update": "2015-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01213095",
      "title": "Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)",
      "status": "COMPLETED",
      "last_update": "2016-04-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01238146",
      "title": "Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2013-06-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01239394",
      "title": "Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01282424",
      "title": "Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas",
      "status": "COMPLETED",
      "last_update": "2019-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01317901",
      "title": "A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-06-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01326702",
      "title": "Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-12-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01381692",
      "title": "Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-10-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01419795",
      "title": "Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01427114",
      "title": "R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)",
      "status": "COMPLETED",
      "last_update": "2021-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01429025",
      "title": "Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-10-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01460602",
      "title": "Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2020-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01479842",
      "title": "Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01514344",
      "title": "Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01611259",
      "title": "Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue",
      "status": "COMPLETED",
      "last_update": "2017-11-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01647971",
      "title": "Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-11-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01678404",
      "title": "131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2012-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01682044",
      "title": "Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01701232",
      "title": "Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-11-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01732913",
      "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2018-11-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01732926",
      "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2018-11-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01744912",
      "title": "Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies",
      "status": "TERMINATED",
      "last_update": "2022-05-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01805037",
      "title": "Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas",
      "status": "TERMINATED",
      "last_update": "2021-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01808599",
      "title": "Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01812005",
      "title": "Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01938001",
      "title": "Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)",
      "status": "COMPLETED",
      "last_update": "2023-02-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01974440",
      "title": "A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01995669",
      "title": "Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01996865",
      "title": "Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.",
      "status": "COMPLETED",
      "last_update": "2025-07-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02049541",
      "title": "Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02168907",
      "title": "CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02180711",
      "title": "Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02213913",
      "title": "Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas",
      "status": "COMPLETED",
      "last_update": "2026-03-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02257242",
      "title": "Vincristine Sulfate Liposome Injection (Marqibo\u00ae), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-02-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02281279",
      "title": "Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2016-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02339922",
      "title": "Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02384954",
      "title": "QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab",
      "status": "TERMINATED",
      "last_update": "2024-07-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02433795",
      "title": "Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)",
      "status": "COMPLETED",
      "last_update": "2026-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02501473",
      "title": "Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)",
      "status": "TERMINATED",
      "last_update": "2020-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02532257",
      "title": "Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02576275",
      "title": "A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)",
      "status": "WITHDRAWN",
      "last_update": "2021-03-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02623920",
      "title": "Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2017-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02657447",
      "title": "Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)",
      "status": "WITHDRAWN",
      "last_update": "2019-01-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02853370",
      "title": "Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02914938",
      "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2023-05-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02924402",
      "title": "Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02983097",
      "title": "Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP",
      "status": "TERMINATED",
      "last_update": "2018-01-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02992522",
      "title": "Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03010358",
      "title": "Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-08-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03019666",
      "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL",
      "status": "COMPLETED",
      "last_update": "2022-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03078855",
      "title": "A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-09-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03198026",
      "title": "Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03269552",
      "title": "Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma",
      "status": "TERMINATED",
      "last_update": "2020-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03276468",
      "title": "Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas",
      "status": "COMPLETED",
      "last_update": "2023-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03277729",
      "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03322865",
      "title": "Obinutuzumab in Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03424122",
      "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",
      "status": "COMPLETED",
      "last_update": "2025-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03432741",
      "title": "Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer",
      "status": "TERMINATED",
      "last_update": "2025-05-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03474744",
      "title": "Copanlisib and Rituximab in Marginal Zone Lymphoma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03520920",
      "title": "BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)",
      "status": "COMPLETED",
      "last_update": "2024-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03697512",
      "title": "MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03888105",
      "title": "A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03919175",
      "title": "Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04189952",
      "title": "Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-05-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04212013",
      "title": "A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04268277",
      "title": "Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY",
      "status": "TERMINATED",
      "last_update": "2026-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04323956",
      "title": "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04416451",
      "title": "A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04433156",
      "title": "VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04447716",
      "title": "An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04542824",
      "title": "Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04578600",
      "title": "CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04599634",
      "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-02-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04646395",
      "title": "Study of Acalabrutinib and Tafasitamab in MZL Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04659044",
      "title": "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04680052",
      "title": "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04735471",
      "title": "A Phase 1 Study of ADI-001 in B Cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-06-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04745832",
      "title": "Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)",
      "status": "TERMINATED",
      "last_update": "2024-11-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04796922",
      "title": "To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)",
      "status": "WITHDRAWN",
      "last_update": "2022-07-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04799275",
      "title": "Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04806035",
      "title": "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2024-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04850495",
      "title": "Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05003141",
      "title": "PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies",
      "status": "UNKNOWN",
      "last_update": "2022-03-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05025800",
      "title": "ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05073250",
      "title": "IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.",
      "status": "UNKNOWN",
      "last_update": "2023-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05100862",
      "title": "A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05169658",
      "title": "Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05653271",
      "title": "ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05735834",
      "title": "Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05783596",
      "title": "Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05821088",
      "title": "Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05934097",
      "title": "FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2023-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06064344",
      "title": "RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-10-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06647732",
      "title": "Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07024147",
      "title": "JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07247383",
      "title": "Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07299331",
      "title": "Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07480863",
      "title": "Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07583810",
      "title": "Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07638722",
      "title": "Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07654465",
      "title": "Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07714421",
      "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 7,
     "n_observational": 1,
     "n_active": 3,
     "n_withdrawn": 1,
     "trials": [
      {
       "nct": "NCT04186520",
       "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-02-23",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07225439",
       "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)",
       "status": "RECRUITING",
       "last_update": "2026-09-09",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00176475",
       "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease",
       "status": "TERMINATED",
       "last_update": "2013-09-17",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00521261",
       "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
       "status": "WITHDRAWN",
       "last_update": "2014-03-05",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT00621452",
       "title": "Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma",
       "status": "COMPLETED",
       "last_update": "2014-08-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03019666",
       "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL",
       "status": "COMPLETED",
       "last_update": "2022-11-04",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03277729",
       "title": "A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-06-22",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD20",
     "rituximab",
     "obinutuzumab",
     "tafasitamab"
    ]
   },
   "PI3K": {
    "n": 32,
    "n_observational": 0,
    "n_active": 3,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT01282424",
      "title": "Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas",
      "status": "COMPLETED",
      "last_update": "2019-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01306643",
      "title": "Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-11-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01732913",
      "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2018-11-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01732926",
      "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2018-11-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02049541",
      "title": "Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02242045",
      "title": "Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)",
      "status": "COMPLETED",
      "last_update": "2021-03-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02258555",
      "title": "Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma",
      "status": "TERMINATED",
      "last_update": "2015-10-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02332980",
      "title": "Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas",
      "status": "COMPLETED",
      "last_update": "2026-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02576275",
      "title": "A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)",
      "status": "WITHDRAWN",
      "last_update": "2021-03-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02793583",
      "title": "Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma",
      "status": "TERMINATED",
      "last_update": "2022-07-21",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03133221",
      "title": "1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2025-06-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03144674",
      "title": "A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)",
      "status": "COMPLETED",
      "last_update": "2025-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03314922",
      "title": "A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)",
      "status": "COMPLETED",
      "last_update": "2023-08-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03364231",
      "title": "Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03424122",
      "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",
      "status": "COMPLETED",
      "last_update": "2025-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03432741",
      "title": "Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer",
      "status": "TERMINATED",
      "last_update": "2025-05-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03474744",
      "title": "Copanlisib and Rituximab in Marginal Zone Lymphoma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03768505",
      "title": "Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)",
      "status": "TERMINATED",
      "last_update": "2024-12-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03884998",
      "title": "Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03886649",
      "title": "Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.",
      "status": "TERMINATED",
      "last_update": "2022-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03919175",
      "title": "Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04282018",
      "title": "Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab",
      "status": "COMPLETED",
      "last_update": "2026-02-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04298879",
      "title": "IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-06-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04323956",
      "title": "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04431089",
      "title": "Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2021-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04508647",
      "title": "Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04635683",
      "title": "Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2022-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04745832",
      "title": "Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)",
      "status": "TERMINATED",
      "last_update": "2024-11-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04796922",
      "title": "To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)",
      "status": "WITHDRAWN",
      "last_update": "2022-07-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04849351",
      "title": "Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05073250",
      "title": "IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.",
      "status": "UNKNOWN",
      "last_update": "2023-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "PI3K",
     "umbralisib",
     "copanlisib",
     "idelalisib",
     "zandelisib",
     "parsaclisib"
    ]
   },
   "CD19": {
    "n": 27,
    "n_observational": 1,
    "n_active": 15,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04186520",
      "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-02-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04545762",
      "title": "Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04830137",
      "title": "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05281809",
      "title": "Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia",
      "status": "RECRUITING",
      "last_update": "2025-01-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05643742",
      "title": "A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2025-11-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06026319",
      "title": "CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06533579",
      "title": "Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06544265",
      "title": "SynKIR-310 for Relapsed/Refractory B-NHL",
      "status": "RECRUITING",
      "last_update": "2026-04-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003874",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00816413",
      "title": "Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer",
      "status": "WITHDRAWN",
      "last_update": "2023-08-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00889408",
      "title": "DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00989586",
      "title": "Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-02-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01815749",
      "title": "Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02134262",
      "title": "Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes",
      "status": "UNKNOWN",
      "last_update": "2014-11-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02153580",
      "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02568553",
      "title": "Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-11-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03105336",
      "title": "A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-12-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04450069",
      "title": "CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2024-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04464200",
      "title": "19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04488354",
      "title": "Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T",
      "status": "COMPLETED",
      "last_update": "2026-04-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04806035",
      "title": "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2024-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05336409",
      "title": "A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2025-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05821088",
      "title": "Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05878184",
      "title": "Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06561425",
      "title": "A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-06-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07024147",
      "title": "JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07713459",
      "title": "A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 8,
     "n_observational": 0,
     "n_active": 6,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT04186520",
       "title": "CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-02-23",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04545762",
       "title": "Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-06-22",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05281809",
       "title": "Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia",
       "status": "RECRUITING",
       "last_update": "2025-01-13",
       "phase": "PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06026319",
       "title": "CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma",
       "status": "RECRUITING",
       "last_update": "2026-03-16",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02134262",
       "title": "Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes",
       "status": "UNKNOWN",
       "last_update": "2014-11-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02153580",
       "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-10-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04464200",
       "title": "19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-08-27",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04488354",
       "title": "Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T",
       "status": "COMPLETED",
       "last_update": "2026-04-08",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CD19",
     "CD19 CAR",
     "axicabtagene",
     "Yescarta",
     "lisocabtagene"
    ]
   },
   "lenalidomide": {
    "n": 55,
    "n_observational": 4,
    "n_active": 26,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT04110301",
      "title": "MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)",
      "status": "RECRUITING",
      "last_update": "2024-11-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04669171",
      "title": "A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04792502",
      "title": "Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04830137",
      "title": "A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04834024",
      "title": "MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-11-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05846750",
      "title": "Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2023-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06006117",
      "title": "Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06082102",
      "title": "Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-09-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06149286",
      "title": "A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06454968",
      "title": "Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.",
      "status": "RECRUITING",
      "last_update": "2024-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06792825",
      "title": "HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06793189",
      "title": "MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL",
      "status": "RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07208981",
      "title": "Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL",
      "status": "RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07448324",
      "title": "Orelabrutinib Combined With Rituximab \u00b1 Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL",
      "status": "RECRUITING",
      "last_update": "2026-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00031941",
      "title": "CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy",
      "status": "COMPLETED",
      "last_update": "2012-03-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00695786",
      "title": "Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00783367",
      "title": "Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas",
      "status": "COMPLETED",
      "last_update": "2023-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00784927",
      "title": "Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-10-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00901615",
      "title": "Lenalidomide and R-CHOP in B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-08-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00923663",
      "title": "Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type",
      "status": "UNKNOWN",
      "last_update": "2010-09-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01045928",
      "title": "Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2015-11-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01075321",
      "title": "Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2020-10-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01076543",
      "title": "Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-10-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01116154",
      "title": "Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2010-12-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01121757",
      "title": "Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma",
      "status": "TERMINATED",
      "last_update": "2016-09-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01254578",
      "title": "Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers",
      "status": "COMPLETED",
      "last_update": "2017-09-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01419795",
      "title": "Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01429025",
      "title": "Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-10-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01611259",
      "title": "Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue",
      "status": "COMPLETED",
      "last_update": "2017-11-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01744912",
      "title": "Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies",
      "status": "TERMINATED",
      "last_update": "2022-05-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01938001",
      "title": "Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)",
      "status": "COMPLETED",
      "last_update": "2023-02-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01955499",
      "title": "Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01995669",
      "title": "Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01996865",
      "title": "Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.",
      "status": "COMPLETED",
      "last_update": "2025-07-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02180711",
      "title": "Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02213913",
      "title": "Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas",
      "status": "COMPLETED",
      "last_update": "2026-03-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02281279",
      "title": "Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2016-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02532257",
      "title": "Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02568553",
      "title": "Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-11-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02983097",
      "title": "Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP",
      "status": "TERMINATED",
      "last_update": "2018-01-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02992522",
      "title": "Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03015896",
      "title": "Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03031483",
      "title": "Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-01-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04447716",
      "title": "An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04542824",
      "title": "Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04578600",
      "title": "CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04604028",
      "title": "Lenalidomide and Low-dose Cyclophosphamide for MALT Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2020-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04635683",
      "title": "Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2022-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04680052",
      "title": "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04903197",
      "title": "Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05025800",
      "title": "ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05100862",
      "title": "A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05821088",
      "title": "Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07299331",
      "title": "Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07654465",
      "title": "Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "lenalidomide",
     "R2"
    ]
   },
   "BCL-2": {
    "n": 28,
    "n_observational": 2,
    "n_active": 15,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04840602",
      "title": "Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05131022",
      "title": "A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06510309",
      "title": "Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06708897",
      "title": "A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06859008",
      "title": "Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07231952",
      "title": "A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenstr\u00f6m's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)",
      "status": "RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054639",
      "title": "Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00060112",
      "title": "Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma",
      "status": "TERMINATED",
      "last_update": "2013-01-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02992522",
      "title": "Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03162536",
      "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03276468",
      "title": "Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas",
      "status": "COMPLETED",
      "last_update": "2023-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03547115",
      "title": "A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML",
      "status": "TERMINATED",
      "last_update": "2026-03-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03583424",
      "title": "Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03886649",
      "title": "Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.",
      "status": "TERMINATED",
      "last_update": "2022-04-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04072458",
      "title": "A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-02-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04416451",
      "title": "A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04447716",
      "title": "An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04599634",
      "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-02-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04659044",
      "title": "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04799275",
      "title": "Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05024045",
      "title": "Study of Oral LOXO-338 in Patients With Advanced Blood Cancers",
      "status": "COMPLETED",
      "last_update": "2026-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05107856",
      "title": "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2024-01-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05665530",
      "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05734495",
      "title": "Pirtobrutinib and Venetoclax in Waldenstr\u00f6m Macroglobulinemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05753501",
      "title": "Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05828589",
      "title": "A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies",
      "status": "TERMINATED",
      "last_update": "2026-07-14",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07387471",
      "title": "Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenstr\u00f6m Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "BCL-2",
     "venetoclax"
    ]
   },
   "CD20xCD3": {
    "n": 17,
    "n_observational": 0,
    "n_active": 15,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04792502",
      "title": "Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06006117",
      "title": "Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06149286",
      "title": "A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06442475",
      "title": "Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06563505",
      "title": "A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06563596",
      "title": "Epco, Zanu, Ritux for R/R FL or MZL",
      "status": "RECRUITING",
      "last_update": "2026-02-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06569680",
      "title": "Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-11-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06796998",
      "title": "Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)",
      "status": "RECRUITING",
      "last_update": "2025-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06905509",
      "title": "Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03625037",
      "title": "First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03888105",
      "title": "A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04358458",
      "title": "First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2024-10-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04542824",
      "title": "Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05169658",
      "title": "Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05783596",
      "title": "Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07638722",
      "title": "Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07714421",
      "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "glofitamab",
     "mosunetuzumab",
     "epcoritamab",
     "odronextamab"
    ]
   },
   "Helicobacter eradication": {
    "n": 17,
    "n_observational": 3,
    "n_active": 2,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT06228963",
      "title": "Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002682",
      "title": "Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach",
      "status": "COMPLETED",
      "last_update": "2018-10-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003151",
      "title": "Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma",
      "status": "COMPLETED",
      "last_update": "2012-07-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003938",
      "title": "Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2012-09-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00154440",
      "title": "Helicobacter - Lymphoma - Radiation Part I: Eradication, Part II: Radiation",
      "status": "UNKNOWN",
      "last_update": "2007-03-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00201422",
      "title": "Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma",
      "status": "COMPLETED",
      "last_update": "2016-03-28",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00324324",
      "title": "Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-05-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00327132",
      "title": "Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric MALT Lymphoma for Treatment Outcome",
      "status": "COMPLETED",
      "last_update": "2016-03-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00373646",
      "title": "Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients",
      "status": "COMPLETED",
      "last_update": "2009-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00445497",
      "title": "Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia",
      "status": "UNKNOWN",
      "last_update": "2013-08-12",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00923663",
      "title": "Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type",
      "status": "UNKNOWN",
      "last_update": "2010-09-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01101412",
      "title": "Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2013-02-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01820910",
      "title": "Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment",
      "status": "COMPLETED",
      "last_update": "2026-04-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02388581",
      "title": "First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL",
      "status": "UNKNOWN",
      "last_update": "2016-03-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03432741",
      "title": "Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer",
      "status": "TERMINATED",
      "last_update": "2025-05-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04604028",
      "title": "Lenalidomide and Low-dose Cyclophosphamide for MALT Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2020-10-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07144657",
      "title": "Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 0,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": []
    },
    "synonyms_searched": [
     "Helicobacter",
     "eradication",
     "antibiotic"
    ]
   },
   "bendamustine": {
    "n": 31,
    "n_observational": 2,
    "n_active": 8,
    "n_withdrawn": 4,
    "trials": [
     {
      "nct": "NCT04223765",
      "title": "Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.",
      "status": "RECRUITING",
      "last_update": "2026-01-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06006117",
      "title": "Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06191887",
      "title": "B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-02-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06504940",
      "title": "Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)",
      "status": "RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07208981",
      "title": "Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL",
      "status": "RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00877214",
      "title": "Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas",
      "status": "UNKNOWN",
      "last_update": "2024-08-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00880815",
      "title": "Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2019-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00991211",
      "title": "Bendamustine Plus Rituximab Versus CHOP Plus Rituximab",
      "status": "COMPLETED",
      "last_update": "2024-08-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01015248",
      "title": "Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-09-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01110135",
      "title": "Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma",
      "status": "COMPLETED",
      "last_update": "2017-05-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01238146",
      "title": "Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2013-06-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01317901",
      "title": "A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-06-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01326702",
      "title": "Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-12-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01429025",
      "title": "Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-10-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01479842",
      "title": "Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01732926",
      "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2018-11-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01974440",
      "title": "A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02134262",
      "title": "Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes",
      "status": "UNKNOWN",
      "last_update": "2014-11-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02153580",
      "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02168907",
      "title": "CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02257242",
      "title": "Vincristine Sulfate Liposome Injection (Marqibo\u00ae), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-02-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02433795",
      "title": "Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)",
      "status": "COMPLETED",
      "last_update": "2026-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02576275",
      "title": "A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)",
      "status": "WITHDRAWN",
      "last_update": "2021-03-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02623920",
      "title": "Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2017-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02793583",
      "title": "Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma",
      "status": "TERMINATED",
      "last_update": "2022-07-21",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02853370",
      "title": "Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02996773",
      "title": "Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine",
      "status": "COMPLETED",
      "last_update": "2025-11-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03424122",
      "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",
      "status": "COMPLETED",
      "last_update": "2025-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04745832",
      "title": "Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)",
      "status": "TERMINATED",
      "last_update": "2024-11-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05934097",
      "title": "FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2023-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07008053",
      "title": "BR Combined With OR in Treatment-na\u00efve Marginal Zone Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 4,
     "n_observational": 0,
     "n_active": 3,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT04223765",
       "title": "Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.",
       "status": "RECRUITING",
       "last_update": "2026-01-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06191887",
       "title": "B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies",
       "status": "RECRUITING",
       "last_update": "2026-02-13",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02134262",
       "title": "Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes",
       "status": "UNKNOWN",
       "last_update": "2014-11-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02153580",
       "title": "Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-10-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "bendamustine"
    ]
   }
  },
  "by_drug": {
   "ACALABRUTINIB": {
    "n": 9,
    "n_observational": 1,
    "n_active": 4,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04883437",
      "title": "Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02180711",
      "title": "Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02362035",
      "title": "ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-05-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03162536",
      "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04116437",
      "title": "Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment",
      "status": "COMPLETED",
      "last_update": "2026-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04189952",
      "title": "Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-05-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04646395",
      "title": "Study of Acalabrutinib and Tafasitamab in MZL Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04836832",
      "title": "Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2022-06-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "EPCORITAMAB": {
    "n": 7,
    "n_observational": 0,
    "n_active": 6,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06563596",
      "title": "Epco, Zanu, Ritux for R/R FL or MZL",
      "status": "RECRUITING",
      "last_update": "2026-02-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06796998",
      "title": "Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)",
      "status": "RECRUITING",
      "last_update": "2025-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06905509",
      "title": "Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03625037",
      "title": "First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04358458",
      "title": "First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2024-10-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04542824",
      "title": "Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07714421",
      "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "GLOFITAMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05783596",
      "title": "Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "IBRUTINIB": {
    "n": 25,
    "n_observational": 1,
    "n_active": 8,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT04840602",
      "title": "Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00849654",
      "title": "Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01479842",
      "title": "Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01955499",
      "title": "Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01974440",
      "title": "A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01980628",
      "title": "Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-10-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02109224",
      "title": "Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection",
      "status": "TERMINATED",
      "last_update": "2015-08-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02332980",
      "title": "Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas",
      "status": "COMPLETED",
      "last_update": "2026-06-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02381080",
      "title": "Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy",
      "status": "COMPLETED",
      "last_update": "2017-06-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02532257",
      "title": "Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02927964",
      "title": "TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-10-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02950220",
      "title": "Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03088878",
      "title": "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-02-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03093831",
      "title": "Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma",
      "status": "TERMINATED",
      "last_update": "2023-10-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03144674",
      "title": "A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)",
      "status": "COMPLETED",
      "last_update": "2025-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03162536",
      "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03198026",
      "title": "Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03424122",
      "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",
      "status": "COMPLETED",
      "last_update": "2025-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03479268",
      "title": "Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03697512",
      "title": "MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04043845",
      "title": "ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2020-02-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04116437",
      "title": "Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment",
      "status": "COMPLETED",
      "last_update": "2026-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04212013",
      "title": "A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04665115",
      "title": "Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)",
      "status": "WITHDRAWN",
      "last_update": "2022-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LFB-R603": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04635683",
      "title": "Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2022-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04806035",
      "title": "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2024-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "MOSUNETUZUMAB": {
    "n": 7,
    "n_observational": 0,
    "n_active": 6,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04792502",
      "title": "Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06006117",
      "title": "Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06442475",
      "title": "Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06563505",
      "title": "A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06569680",
      "title": "Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-11-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05169658",
      "title": "Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07638722",
      "title": "Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OBINUTUZUMAB": {
    "n": 25,
    "n_observational": 2,
    "n_active": 16,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT04883437",
      "title": "Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05846750",
      "title": "Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2023-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06134284",
      "title": "Clinical Study of OR for Second-line Treatment of Refractory MZL",
      "status": "RECRUITING",
      "last_update": "2024-06-11",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06454968",
      "title": "Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.",
      "status": "RECRUITING",
      "last_update": "2024-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06504940",
      "title": "Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)",
      "status": "RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06513234",
      "title": "Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas",
      "status": "RECRUITING",
      "last_update": "2024-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06566807",
      "title": "Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06592170",
      "title": "Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)",
      "status": "RECRUITING",
      "last_update": "2024-09-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06793189",
      "title": "MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL",
      "status": "RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07355699",
      "title": "Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01995669",
      "title": "Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-06-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02992522",
      "title": "Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03010358",
      "title": "Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-08-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03198026",
      "title": "Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03276468",
      "title": "Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas",
      "status": "COMPLETED",
      "last_update": "2023-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03322865",
      "title": "Obinutuzumab in Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03432741",
      "title": "Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer",
      "status": "TERMINATED",
      "last_update": "2025-05-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04578600",
      "title": "CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-04-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04599634",
      "title": "Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-02-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04796922",
      "title": "To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)",
      "status": "WITHDRAWN",
      "last_update": "2022-07-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05100862",
      "title": "A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05169658",
      "title": "Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-05-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05653271",
      "title": "ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05783596",
      "title": "Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07480863",
      "title": "Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OCARATUZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00003874",
      "title": "Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia",
      "status": "COMPLETED",
      "last_update": "2011-11-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ODRONEXTAMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06149286",
      "title": "A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03888105",
      "title": "A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OFATUMUMAB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT01119794",
      "title": "Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab",
      "status": "TERMINATED",
      "last_update": "2015-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01239394",
      "title": "Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-10-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01263418",
      "title": "Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas",
      "status": "WITHDRAWN",
      "last_update": "2015-10-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ORELABRUTINIB": {
    "n": 23,
    "n_observational": 1,
    "n_active": 23,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06082102",
      "title": "Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-09-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06134284",
      "title": "Clinical Study of OR for Second-line Treatment of Refractory MZL",
      "status": "RECRUITING",
      "last_update": "2024-06-11",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06228963",
      "title": "Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06454968",
      "title": "Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.",
      "status": "RECRUITING",
      "last_update": "2024-06-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06478472",
      "title": "Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy",
      "status": "RECRUITING",
      "last_update": "2024-07-29",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06503276",
      "title": "The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy",
      "status": "RECRUITING",
      "last_update": "2024-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06504940",
      "title": "Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)",
      "status": "RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06513234",
      "title": "Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas",
      "status": "RECRUITING",
      "last_update": "2024-07-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06566807",
      "title": "Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-08-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06700798",
      "title": "Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL\uff1a A Randomized, Open Phase II Trial",
      "status": "RECRUITING",
      "last_update": "2025-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06793189",
      "title": "MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL",
      "status": "RECRUITING",
      "last_update": "2026-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07022223",
      "title": "Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07208981",
      "title": "Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL",
      "status": "RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07355699",
      "title": "Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07372365",
      "title": "Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Na\u00efve MZL.",
      "status": "RECRUITING",
      "last_update": "2026-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07441993",
      "title": "Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL",
      "status": "RECRUITING",
      "last_update": "2026-03-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07448324",
      "title": "Orelabrutinib Combined With Rituximab \u00b1 Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL",
      "status": "RECRUITING",
      "last_update": "2026-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07554898",
      "title": "Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage \u2160-\u2161 MALT Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06583837",
      "title": "Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07008053",
      "title": "BR Combined With OR in Treatment-na\u00efve Marginal Zone Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07247383",
      "title": "Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07480863",
      "title": "Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07705308",
      "title": "A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PIRTOBRUTINIB": {
    "n": 8,
    "n_observational": 0,
    "n_active": 5,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05602363",
      "title": "AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-12-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05990465",
      "title": "LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06390956",
      "title": "Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)",
      "status": "RECRUITING",
      "last_update": "2025-12-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07231952",
      "title": "A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenstr\u00f6m's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)",
      "status": "RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04849416",
      "title": "A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)",
      "status": "COMPLETED",
      "last_update": "2026-02-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05024045",
      "title": "Study of Oral LOXO-338 in Patients With Advanced Blood Cancers",
      "status": "COMPLETED",
      "last_update": "2026-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05734495",
      "title": "Pirtobrutinib and Venetoclax in Waldenstr\u00f6m Macroglobulinemia",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "RITUXIMAB": {
    "n": 192,
    "n_observational": 8,
    "n_active": 48,
    "n_withdrawn": 12,
    "trials": [
     {
      "nct": "NCT04669171",
      "title": "A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04834024",
      "title": "MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular Lymphoma",
      "status": "RECRUITING",
      "last_update": "2024-11-20",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04840602",
      "title": "Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06006117",
      "title": "Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06082102",
      "title": "Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-09-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06134284",
      "title": "Clinical Study of OR for Second-line Treatment of Refractory MZL",
      "status": "RECRUITING",
      "last_update": "2024-06-11",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06149286",
      "title": "A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06190301",
      "title": "RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06350318",
      "title": "Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06390956",
      "title": "Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)",
      "status": "RECRUITING",
      "last_update": "2025-12-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06478472",
      "title": "Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy",
      "status": "RECRUITING",
      "last_update": "2024-07-29",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06504940",
      "title": "Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)",
      "status": "RECRUITING",
      "last_update": "2026-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06510309",
      "title": "Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06563596",
      "title": "Epco, Zanu, Ritux for R/R FL or MZL",
      "status": "RECRUITING",
      "last_update": "2026-02-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06700798",
      "title": "Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL\uff1a A Randomized, Open Phase II Trial",
      "status": "RECRUITING",
      "last_update": "2025-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06792825",
      "title": "HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06905509",
      "title": "Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07022223",
      "title": "Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2025-06-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07208981",
      "title": "Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL",
      "status": "RECRUITING",
      "last_update": "2025-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07225439",
      "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07231952",
      "title": "A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenstr\u00f6m's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)",
      "status": "RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07355699",
      "title": "Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-01-21",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07448324",
      "title": "Orelabrutinib Combined With Rituximab \u00b1 Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL",
      "status": "RECRUITING",
      "last_update": "2026-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07691606",
      "title": "A Study of ARC-02 in B-cell NHL",
      "status": "RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00002663",
      "title": "Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies",
      "status": "COMPLETED",
      "last_update": "2023-02-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003356",
      "title": "Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-10-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003605",
      "title": "Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2015-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003663",
      "title": "Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2015-08-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003963",
      "title": "Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2020-08-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004112",
      "title": "Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-09-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004260",
      "title": "Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2011-08-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005592",
      "title": "Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-10-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005601",
      "title": "Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-12-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00007852",
      "title": "Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-09-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00007865",
      "title": "Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-12-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00012298",
      "title": "Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-08-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00017381",
      "title": "Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-01-09",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00026182",
      "title": "Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00026351",
      "title": "Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00031642",
      "title": "Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2023-12-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00033423",
      "title": "Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2013-12-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00040950",
      "title": "Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00052936",
      "title": "Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-05-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00054639",
      "title": "Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00058227",
      "title": "Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00058292",
      "title": "Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2012-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00062296",
      "title": "Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00068315",
      "title": "Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2013-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00072514",
      "title": "Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2017-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00075946",
      "title": "Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-02-01",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00080886",
      "title": "Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-10-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00080925",
      "title": "T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2012-03-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00087425",
      "title": "Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2015-04-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00088881",
      "title": "Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2017-05-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00093769",
      "title": "Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2012-10-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110149",
      "title": "Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2017-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00117156",
      "title": "Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00119392",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00142116",
      "title": "Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia",
      "status": "COMPLETED",
      "last_update": "2014-06-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00176475",
      "title": "Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease",
      "status": "TERMINATED",
      "last_update": "2013-09-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00210353",
      "title": "Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-06-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244855",
      "title": "Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-05-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244946",
      "title": "Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-03-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00244985",
      "title": "Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00265928",
      "title": "Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2008-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00274794",
      "title": "VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL",
      "status": "COMPLETED",
      "last_update": "2011-03-29",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00278161",
      "title": "Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-11-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00278408",
      "title": "Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-08-26",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00278421",
      "title": "Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-03-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00288067",
      "title": "Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2014-10-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00295932",
      "title": "Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-11-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00387959",
      "title": "Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00392691",
      "title": "Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment",
      "status": "COMPLETED",
      "last_update": "2019-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00397800",
      "title": "Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2012-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00398372",
      "title": "Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment",
      "status": "COMPLETED",
      "last_update": "2011-06-02",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00416923",
      "title": "Intrathecal Rituximab in Treating Patients With Recurrent CNS Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-02-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00425802",
      "title": "Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "COMPLETED",
      "last_update": "2017-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00438880",
      "title": "Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00453102",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-01-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00493454",
      "title": "Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas",
      "status": "TERMINATED",
      "last_update": "2013-05-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00496873",
      "title": "Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan",
      "status": "COMPLETED",
      "last_update": "2023-03-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00521261",
      "title": "Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2014-03-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00536978",
      "title": "Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies",
      "status": "COMPLETED",
      "last_update": "2020-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00546377",
      "title": "Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer",
      "status": "COMPLETED",
      "last_update": "2016-05-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00551239",
      "title": "Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2020-10-19",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00556699",
      "title": "A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00577278",
      "title": "A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan",
      "status": "COMPLETED",
      "last_update": "2024-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00601718",
      "title": "Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-05-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00617929",
      "title": "Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00625729",
      "title": "Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2017-12-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00656812",
      "title": "Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-12-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00691015",
      "title": "Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2017-06-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00691652",
      "title": "Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2019-11-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00695786",
      "title": "Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-10-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00711828",
      "title": "Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-04-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00720135",
      "title": "Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00720876",
      "title": "Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00726700",
      "title": "Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00772668",
      "title": "Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL",
      "status": "TERMINATED",
      "last_update": "2017-12-11",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00783367",
      "title": "Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas",
      "status": "COMPLETED",
      "last_update": "2023-03-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00784927",
      "title": "Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-10-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00801281",
      "title": "First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.",
      "status": "COMPLETED",
      "last_update": "2017-07-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00818961",
      "title": "Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2013-12-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00867529",
      "title": "Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-01-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00877214",
      "title": "Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas",
      "status": "UNKNOWN",
      "last_update": "2024-08-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00880815",
      "title": "Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant",
      "status": "COMPLETED",
      "last_update": "2019-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00927797",
      "title": "Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)",
      "status": "UNKNOWN",
      "last_update": "2009-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00980395",
      "title": "Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-12-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00991211",
      "title": "Bendamustine Plus Rituximab Versus CHOP Plus Rituximab",
      "status": "COMPLETED",
      "last_update": "2024-08-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01015248",
      "title": "Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-09-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01044745",
      "title": "Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer",
      "status": "TERMINATED",
      "last_update": "2023-09-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01045928",
      "title": "Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2015-11-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01116232",
      "title": "Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation",
      "status": "TERMINATED",
      "last_update": "2019-03-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01119794",
      "title": "Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab",
      "status": "TERMINATED",
      "last_update": "2015-08-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01213095",
      "title": "Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL)",
      "status": "COMPLETED",
      "last_update": "2016-04-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01238146",
      "title": "Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2013-06-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01282424",
      "title": "Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas",
      "status": "COMPLETED",
      "last_update": "2019-07-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01317901",
      "title": "A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-06-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01326702",
      "title": "Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-12-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01381692",
      "title": "Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-10-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01419795",
      "title": "Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant",
      "status": "TERMINATED",
      "last_update": "2017-07-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01427114",
      "title": "R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML)",
      "status": "COMPLETED",
      "last_update": "2021-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01429025",
      "title": "Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2019-10-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01460602",
      "title": "Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2020-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01479842",
      "title": "Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01514344",
      "title": "Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-08-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01611259",
      "title": "Rituximab Plus Lenalidomide in Patients With Mucosa Associated Lymphoid Tissue",
      "status": "COMPLETED",
      "last_update": "2017-11-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01647971",
      "title": "Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-11-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01678404",
      "title": "131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2012-09-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01682044",
      "title": "Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01701232",
      "title": "Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-11-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01732913",
      "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2018-11-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01732926",
      "title": "Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas",
      "status": "TERMINATED",
      "last_update": "2018-11-16",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01805037",
      "title": "Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas",
      "status": "TERMINATED",
      "last_update": "2021-09-01",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01808599",
      "title": "Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01812005",
      "title": "Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-06-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01938001",
      "title": "Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)",
      "status": "COMPLETED",
      "last_update": "2023-02-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01974440",
      "title": "A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2025-05-25",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01996865",
      "title": "Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.",
      "status": "COMPLETED",
      "last_update": "2025-07-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02049541",
      "title": "Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02168907",
      "title": "CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02180711",
      "title": "Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02213913",
      "title": "Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas",
      "status": "COMPLETED",
      "last_update": "2026-03-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02257242",
      "title": "Vincristine Sulfate Liposome Injection (Marqibo\u00ae), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-02-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02281279",
      "title": "Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2016-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02339922",
      "title": "Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02384954",
      "title": "QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab",
      "status": "TERMINATED",
      "last_update": "2024-07-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02433795",
      "title": "Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)",
      "status": "COMPLETED",
      "last_update": "2026-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02501473",
      "title": "Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)",
      "status": "TERMINATED",
      "last_update": "2020-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02532257",
      "title": "Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-09-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02576275",
      "title": "A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)",
      "status": "WITHDRAWN",
      "last_update": "2021-03-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02623920",
      "title": "Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2017-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02657447",
      "title": "Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)",
      "status": "WITHDRAWN",
      "last_update": "2019-01-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02853370",
      "title": "Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2023-02-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02914938",
      "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2023-05-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02983097",
      "title": "Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP",
      "status": "TERMINATED",
      "last_update": "2018-01-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03019666",
      "title": "Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL",
      "status": "COMPLETED",
      "last_update": "2022-11-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03078855",
      "title": "A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-09-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03269552",
      "title": "Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma",
      "status": "TERMINATED",
      "last_update": "2020-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03424122",
      "title": "INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)",
      "status": "COMPLETED",
      "last_update": "2025-08-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03432741",
      "title": "Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer",
      "status": "TERMINATED",
      "last_update": "2025-05-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03474744",
      "title": "Copanlisib and Rituximab in Marginal Zone Lymphoma Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03520920",
      "title": "BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)",
      "status": "COMPLETED",
      "last_update": "2024-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03697512",
      "title": "MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03919175",
      "title": "Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma",
      "status": "TERMINATED",
      "last_update": "2026-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04189952",
      "title": "Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma",
      "status": "TERMINATED",
      "last_update": "2025-05-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04212013",
      "title": "A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04268277",
      "title": "Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY",
      "status": "TERMINATED",
      "last_update": "2026-02-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04323956",
      "title": "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04416451",
      "title": "A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04433156",
      "title": "VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2026-04-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04447716",
      "title": "An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04542824",
      "title": "Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04659044",
      "title": "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
      "status": "TERMINATED",
      "last_update": "2024-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04680052",
      "title": "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04745832",
      "title": "Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)",
      "status": "TERMINATED",
      "last_update": "2024-11-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04796922",
      "title": "To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)",
      "status": "WITHDRAWN",
      "last_update": "2022-07-18",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04799275",
      "title": "Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04850495",
      "title": "Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05025800",
      "title": "ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05073250",
      "title": "IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.",
      "status": "UNKNOWN",
      "last_update": "2023-05-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05100862",
      "title": "A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05735834",
      "title": "Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05934097",
      "title": "FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2023-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06064344",
      "title": "RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-10-03",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06647732",
      "title": "Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07247383",
      "title": "Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07299331",
      "title": "Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07583810",
      "title": "Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07654465",
      "title": "Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07714421",
      "title": "Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TIRABRUTINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03162536",
      "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TOSITUMOMAB": {
    "n": 2,
    "n_observational": 2,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00073918",
      "title": "Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110071",
      "title": "Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2014-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TOSITUMOMAB 131I": {
    "n": 0,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": []
   },
   "UBLITUXIMAB": {
    "n": 6,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT01647971",
      "title": "Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2022-11-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01744912",
      "title": "Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies",
      "status": "TERMINATED",
      "last_update": "2022-05-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02793583",
      "title": "Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma",
      "status": "TERMINATED",
      "last_update": "2022-07-21",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04508647",
      "title": "Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-03-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04635683",
      "title": "Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma",
      "status": "WITHDRAWN",
      "last_update": "2022-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04806035",
      "title": "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
      "status": "TERMINATED",
      "last_update": "2024-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VECABRUTINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03037645",
      "title": "Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers",
      "status": "TERMINATED",
      "last_update": "2020-10-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VELTUZUMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00596804",
      "title": "Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2021-08-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00989586",
      "title": "Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2017-02-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "YTTRIUM Y 90 IBRITUMOMAB TIUXETAN": {
    "n": 15,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00005592",
      "title": "Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2015-10-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00012298",
      "title": "Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2018-08-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00017381",
      "title": "Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2013-01-09",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00031642",
      "title": "Monoclonal Antibody Therapy in Relapsed Non-Hodgkin's After Chemotherapy and Autologous Stem Cell Transplantation",
      "status": "COMPLETED",
      "last_update": "2023-12-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00033423",
      "title": "Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2013-12-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00058292",
      "title": "Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2012-06-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00088881",
      "title": "Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2017-05-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00110149",
      "title": "Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2017-11-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00119392",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",
      "status": "COMPLETED",
      "last_update": "2018-06-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00392691",
      "title": "Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment",
      "status": "COMPLETED",
      "last_update": "2019-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00397800",
      "title": "Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma",
      "status": "UNKNOWN",
      "last_update": "2012-08-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00438880",
      "title": "Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-02-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00453102",
      "title": "Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2016-01-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00493454",
      "title": "Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas",
      "status": "TERMINATED",
      "last_update": "2013-05-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00577278",
      "title": "A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan",
      "status": "COMPLETED",
      "last_update": "2024-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ZANUBRUTINIB": {
    "n": 20,
    "n_observational": 4,
    "n_active": 12,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04840602",
      "title": "Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-09-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06350318",
      "title": "Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas",
      "status": "RECRUITING",
      "last_update": "2026-02-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06563505",
      "title": "A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-07-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06563596",
      "title": "Epco, Zanu, Ritux for R/R FL or MZL",
      "status": "RECRUITING",
      "last_update": "2026-02-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06859008",
      "title": "Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
      "status": "RECRUITING",
      "last_update": "2026-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02914938",
      "title": "A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma",
      "status": "TERMINATED",
      "last_update": "2023-05-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03162536",
      "title": "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03520920",
      "title": "BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)",
      "status": "COMPLETED",
      "last_update": "2024-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03740529",
      "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL",
      "status": "COMPLETED",
      "last_update": "2026-01-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03846427",
      "title": "Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma",
      "status": "COMPLETED",
      "last_update": "2024-10-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04116437",
      "title": "Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment",
      "status": "COMPLETED",
      "last_update": "2026-01-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04172246",
      "title": "Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies",
      "status": "COMPLETED",
      "last_update": "2025-11-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04282018",
      "title": "Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab",
      "status": "COMPLETED",
      "last_update": "2026-02-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04850495",
      "title": "Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05100862",
      "title": "A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05665530",
      "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-01-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05735834",
      "title": "Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06647732",
      "title": "Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07299331",
      "title": "Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07638722",
      "title": "Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}